Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations Feb 20, 2018
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML Feb 12, 2018
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record Feb 12, 2018
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation Feb 8, 2018
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients Feb 6, 2018
Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product Feb 1, 2018
Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 Jan 25, 2018
